Skip to main content
Katherine Fuh, MD, Obstetrics & Gynecology, Saint Louis, MO, Siteman Cancer Center

KatherineFuhMDPhD

Obstetrics & Gynecology Saint Louis, MO

Gynecologic Oncology

Washington University, Gynecologic Oncology

Dr. Fuh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fuh's full profile

Already have an account?

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Gynecologic Oncology, 2009 - 2012
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Obstetrics and Gynecology, 2005 - 2009
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 2005

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2022 - 2024
  • MO State Medical License
    MO State Medical License 2013 - 2024
  • IL State Medical License
    IL State Medical License 2022 - 2023
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer  
    Ian S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
  • Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer  
    Ian S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research

Lectures

  • Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Aravive to Host Virtual KOL Event on Its Late-Stage Oncology Asset Batiraxcept
    Aravive to Host Virtual KOL Event on Its Late-Stage Oncology Asset BatiraxceptMay 8th, 2023
  • Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
    Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian CancerJanuary 4th, 2023
  • Gynecologic Cancer Clinicians and Researchers Recognized at SGO 2022 Annual Meeting on Women’s Cancer
    Gynecologic Cancer Clinicians and Researchers Recognized at SGO 2022 Annual Meeting on Women’s CancerMarch 21st, 2022
  • Join now to see all

Hospital Affiliations